162 related articles for article (PubMed ID: 25995674)
1. Triple-negative breast cancer that progressed as estrogen receptor-positive skin metastases.
Lee SM; Kang EJ; Kim JH; Yun JM; Sun DS; Ko YH; Won HS
Korean J Intern Med; 2015 May; 30(3):411-4. PubMed ID: 25995674
[No Abstract] [Full Text] [Related]
2. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
5. Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.
Chen QX; Li JJ; Wang XX; Lin PY; Zhang J; Song CG; Shao ZM
Oncotarget; 2017 Jan; 8(4):6206-6215. PubMed ID: 28008158
[TBL] [Abstract][Full Text] [Related]
6. Multidisciplinary considerations in the treatment of triple-negative breast cancer.
Bellon JR; Burstein HJ; Frank ES; Mittendorf EA; King TA
CA Cancer J Clin; 2020 Nov; 70(6):432-442. PubMed ID: 32986241
[No Abstract] [Full Text] [Related]
7. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
[TBL] [Abstract][Full Text] [Related]
8. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer in very young women.
Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
[TBL] [Abstract][Full Text] [Related]
10. Expression and prognostic significance of ECT2 in invasive breast cancer.
Wang HK; Liang JF; Zheng HX; Xiao H
J Clin Pathol; 2018 May; 71(5):442-445. PubMed ID: 29051317
[TBL] [Abstract][Full Text] [Related]
11. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
12. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer.
Connor CS; Kimler BF; Mammen JM; McGinness MK; Wagner JL; Alsop SM; Ward C; Fabian CJ; Khan QJ; Sharma P
J Surg Oncol; 2015 Feb; 111(2):198-202. PubMed ID: 25266871
[TBL] [Abstract][Full Text] [Related]
13. TTF-1 positive breast cancer: a cautionary tale.
Ellery P; Archard N; Saetta A; Gandy M; Falzon M
J Clin Pathol; 2015 Aug; 68(8):665-6. PubMed ID: 25918229
[No Abstract] [Full Text] [Related]
14. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
[TBL] [Abstract][Full Text] [Related]
15. Isolated loss of hormonal receptors in leptomeningeal metastasis from estrogen receptor- and progesterone receptor-positive lobular breast cancer.
Grewal J; Zhou H; Factor R; Kesari S
J Clin Oncol; 2010 May; 28(13):e200-2. PubMed ID: 20124173
[No Abstract] [Full Text] [Related]
16. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?
Aurilio G; Bagnardi V; Graffeo R; Nolè F; Petit JY; Locatelli M; Martella S; Iera M; Rey P; Curigliano G; Rotmensz N; Munzone E; Goldhirsch A
Anticancer Res; 2014 Nov; 34(11):6677-83. PubMed ID: 25368274
[TBL] [Abstract][Full Text] [Related]
17. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes.
Migdady Y; Sakr BJ; Sikov WM; Olszewski AJ
Breast; 2013 Oct; 22(5):793-8. PubMed ID: 23489757
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
[TBL] [Abstract][Full Text] [Related]
20. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
